However, blocking IL-1β or its activating enzyme, caspase-1, prevents lung blockages, suggesting that targeting this pathway could offer therapeutic benefits for SCD-related lung complications [104]. The gene discussed is IL1B; the disease is Schnyder corneal dystrophy.